Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19)

Ming Zhong, Aijun Sun, Ting Xiao, Ge Yao, Ling Sang, Xia Zheng, Jinyan Zhang, Xuejuan Jin, Lei Xu, Wenlong Yang, Peng Wang, Kai Hu, Dingyu Zhang, Junbo Ge
doi: https://doi.org/10.1101/2020.04.15.20066266
Ming Zhong
1Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
2Wuhan JinYinTan Hospital, Wuhan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aijun Sun
3Department of Cardiology, Zhongshan Hospital, Fudan University. Shanghai Institute of Cardiovascular Diseases, Shanghai, China
4Institute of Biomedical Sciences, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ting Xiao
5Intensive Care Unit of the Six Floor of South Building, Wuhan JinYinTan Hospital, Wuhan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ge Yao
5Intensive Care Unit of the Six Floor of South Building, Wuhan JinYinTan Hospital, Wuhan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ling Sang
6The First Affiliated Hospital of GuangZhou Medical University, GuangZhou Institute of Respiratory Health, Department of Critical Care Medicine. Guangzhou,China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xia Zheng
7Department of Critical Care Medicine, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinyan Zhang
3Department of Cardiology, Zhongshan Hospital, Fudan University. Shanghai Institute of Cardiovascular Diseases, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuejuan Jin
3Department of Cardiology, Zhongshan Hospital, Fudan University. Shanghai Institute of Cardiovascular Diseases, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lei Xu
3Department of Cardiology, Zhongshan Hospital, Fudan University. Shanghai Institute of Cardiovascular Diseases, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenlong Yang
3Department of Cardiology, Zhongshan Hospital, Fudan University. Shanghai Institute of Cardiovascular Diseases, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peng Wang
3Department of Cardiology, Zhongshan Hospital, Fudan University. Shanghai Institute of Cardiovascular Diseases, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai Hu
3Department of Cardiology, Zhongshan Hospital, Fudan University. Shanghai Institute of Cardiovascular Diseases, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dingyu Zhang
2Wuhan JinYinTan Hospital, Wuhan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jbge@zs-hospital.sh.cn 1813886398@qq.com
Junbo Ge
3Department of Cardiology, Zhongshan Hospital, Fudan University. Shanghai Institute of Cardiovascular Diseases, Shanghai, China
4Institute of Biomedical Sciences, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jbge@zs-hospital.sh.cn 1813886398@qq.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Object To evaluate the clinical efficacy and safety of α-Lipoic acid (ALA) for critically ill patients with coronavirus disease 2019 (COVID-19).

Methods A randomized, single-blind, group sequential, active-controlled trial was performed at JinYinTan Hospital, Wuhan, China. Between February 2020 and March 2020, 17 patients with critically ill COVID-19 were enrolled in our study. Eligible patients were randomly assigned in a 1:1 ratio to receive either ALA (1200 mg/d, intravenous infusion) once daily plus standard care or standard care plus equal volume saline infusion (placebo) for 7 days. All patients were monitored within the 7 days therapy and followed up to day 30 after therapy. The primary outcome of this study was the Sequential Organ Failure Estimate (SOFA) score, and the secondary outcome was the all-cause mortality within 30 days.

Result Nine patients were randomized to placebo group and 8 patients were randomized to ALA group. SOFA score was similar at baseline, increased from 4.3 to 6.0 in the placebo group and increased from 3.8 to 4.0 in the ALA group (P=0.36) after 7 days. The 30-day all-cause mortality tended to be lower in the ALA group (3/8, 37.5%) compared to that in the placebo group (7/9, 77.8%, P=0.09).

Conclusion In our study, ALA use is associated with lower SOFA score increase and lower 30-day all-cause mortality as compared with the placebo group. Although the mortality rate was two-folds higher in placebo group than in ALA group, only borderline statistical difference was evidenced due to the limited patient number. Future studies with larger patient cohort are warranted to validate the role of ALA in critically ill patients with COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ChiCTR2000029851

Funding Statement

none

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

all data referred to in the manuscript was available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 21, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19)
Ming Zhong, Aijun Sun, Ting Xiao, Ge Yao, Ling Sang, Xia Zheng, Jinyan Zhang, Xuejuan Jin, Lei Xu, Wenlong Yang, Peng Wang, Kai Hu, Dingyu Zhang, Junbo Ge
medRxiv 2020.04.15.20066266; doi: https://doi.org/10.1101/2020.04.15.20066266
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19)
Ming Zhong, Aijun Sun, Ting Xiao, Ge Yao, Ling Sang, Xia Zheng, Jinyan Zhang, Xuejuan Jin, Lei Xu, Wenlong Yang, Peng Wang, Kai Hu, Dingyu Zhang, Junbo Ge
medRxiv 2020.04.15.20066266; doi: https://doi.org/10.1101/2020.04.15.20066266

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (415)
  • Dentistry and Oral Medicine (70)
  • Dermatology (47)
  • Emergency Medicine (144)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4857)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (676)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (630)
  • Health Policy (320)
  • Health Systems and Quality Improvement (206)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5339)
  • Intensive Care and Critical Care Medicine (331)
  • Medical Education (93)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (686)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (208)
  • Oncology (439)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (89)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (780)
  • Public and Global Health (1816)
  • Radiology and Imaging (324)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)